HLS Therapeutics Inc. (TSE:HLS - Get Free Report)'s share price dropped 1.2% during trading on Thursday . The company traded as low as C$3.92 and last traded at C$3.96. Approximately 27,905 shares changed hands during mid-day trading, an increase of 72% from the average daily volume of 16,203 shares. The stock had previously closed at C$4.01.
Analyst Upgrades and Downgrades
Separately, Raymond James raised their price target on shares of HLS Therapeutics from C$4.00 to C$5.00 in a report on Friday, November 22nd.
View Our Latest Stock Report on HLS Therapeutics
HLS Therapeutics Price Performance
The firm has a market cap of C$89.21 million, a PE ratio of -4.02 and a beta of 1.07. The company has a quick ratio of 1.01, a current ratio of 1.56 and a debt-to-equity ratio of 86.50. The stock has a 50 day moving average price of C$4.08 and a two-hundred day moving average price of C$3.74.
HLS Therapeutics Company Profile
(
Get Free Report)
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.
Featured Articles
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
